The ‰uorescence polarization immunoassay (FPIA) method is used to perform measurement of vancomycin hydrochloride (VCM) at many institutions. However, the values measured by the FPIA method are more vulnerable to overestimation than the high performance liquid chromatograpy (HPLC) method. In particular, it was not reported to perform exact therapeutic drug monitoring (TDM) measurement. Since overestimation is likely in patients with renal dysfunction, the HPLC method is preferable for TDM measurement. This study investigates the clinical conditions that lead to overestimation in the FPIA method, paying attention to the relation of clinical laboratory data inspection values and the existence of hemodialysis(HD). Overestimation in the evaluation of TDM using the FPIA method was clinically examined with 116 serum samples obtained from 18 cases medicated with VCM. The relevance between overestimation of patients who had not had HD performed was 72.7±61.7％(means±SD). In short, the overestimation was greatest in HD patients. Since overestimation did not aŠect the evaluation of clinical TDM, such as an eŠect and a side-eŠect, the TDM of VCM was shown to be satisfactorily evaluated by the simple FPIA method.
INTRODUCTION
VCM is an eŠective drug for the treatment of infections caused by methicillin-resistant-staphylococcus aureus (MRSA); however, TDM is a necessary part of this treatment since VCM is nephrotoxic and ototoxic. Presently, at many institutions, TDM for VCM is performed immunologically using polyclonal antibodies (‰uorescence polarization immunoassay: FPIA method) (TDX, Dynabbott Inc.). However, it has been reported that when the concentration of VCM was determined by this method, VCM of a crystalline degradation product 1(CDP 1) cross-reacts with VCM. CDP 1 is the degradation of VCM and has no antimicrobial activity. This CDP 1 leads to an overestimation. And it has been that correct TDM is not performed because the measurement data by FPIA method is more overestimation than the measurement data by HPLC method. 1, 2) Since the excretion of VCM takes a signiˆcantly longer time in patients with nephropathy, CDP 1 is more likely to be produced. Hence, the concentration of VCM could easily be overestimated by the FPIA method in these patients. [3] [4] [5] [6] To date, no reports have described the in‰uence of the overestimation of VCM on hemodialysis (HD), clinical laboratory test results, or the eŠectiveness or side-eŠects of infection therapy.
Hence, the present study investigated (1) diŠer-ences in VCM concentrations determined by the FPIA and HPLC methods, (2) the correlation between overestimation and the eŠectiveness and sideeŠects of therapy, (3) the correlation between overestimation and the patient being on HD.
MATERIALS AND METHODS

Subjects
We examined a total of 116 serum samples collected from 18 patients who received VCM between May 1, 1998 and January 31, 1999 at the Kanto Medical Center NTT EC, Japan. Table 1 shows patient proˆles and the number of samples collected from each patient.
Reagents and Measurement methods
Standard VCM(C 66 H 75 Cl 2 N 9 O 24 ) for research and experiments (manufacturing code: VM16662, donated by Shionogi & Co., Ltd.) were used. Human Serum R (Biowhittaker: lot no. 7M0638) was used as standard human serum, and ristocetin (Sigma Chemical Co., Ltd.) was used as the internal standard. The other chemicals used were all reagent grade. The serum concentrations of VCM were measured by HPLC according to the method of Murayama et al. 5) The serum concentration of VCM was measured by FPIA automatically using an Abbot's TDX.
3. Preparation of a Calibration Curve Standard VCM was dissolved in standard human serum to produce 1, 5, 20, 40 and 60 mg/ml solutions, and a calibration curve was prepared by measuring the VCM concentration of each solution three times.
The HPLC standard curve was made from the concentration and the height of peak value. The HPLC standard curve was Y＝334.2X (R 2 ＝0.9998). The VCM concentration of samples were calculated with the standard curve.
4. Diurnal and Daily Fluctuation, and the Estimation of FPIA Calibration VCM was dissolved in standard human serum to produce 2.5, 10, 30 and 50 mg/ml solutions, and the VCM concentration of each solution was measuredˆve times of the day.
VCM was dissolved in standard human serum to produce 2.5, 10 and 30 mg/ml solutions, and the VCM concentration of each solution was measured on six diŠerent days.
At each concentration, the coe‹cient variation (CV) was less than 1％ for the HPLC method, while it was less than 2.5％ for the FPIA method. The CV was favorable with the HPLC method, except when it reached 2.08％ at the VCM concentration of 10 mg/ ml and 1.17％ at 30 mg/ml. With the FPIA method, the CV was also favorable, except when it reached 2.38％ at 10 mg/ml and 2.54％ at 30 mg/ml.
The estimation of the FPIA calibration stability was done with two lots. The concentrations of the solution VCM was dissolved 4.7, 15.4, 29.7 and 54.1 mg /ml were measured by the calibration of two lots.
The calibration stability of TDX were 5.5％ at 4.7 mg/ml, 1.7％ at 15.4 mg/ml, 1.4％ at 29.7 mg/ml and 54.1 mg/ml with lot 1, and 5.6％ at 4.7 mg/ml, 1.7％ at 15.4, 1.4％ at 29.7 mg/ml and 54.1 mg/ml with other lot. And when it was low concentration, there was a tendency for a certain degree CV to be large.
5. Measurements Using Patient Serum Samples According to the above-mentioned procedure, each serum sample that was stored at -20°C 6) was subjected to HPLC three times. Then, using the calibration curve and the chromatogram, the concentration of VCM was calculated.
On the day of blood sampling, serum was isolated by centrifugation and subjected to analysis using TDX.
6. Calculation of DiŠerences in the Measured Drug Concentrations (Overestimation) between the FPIA and HPLC Methods
The diŠerence in the measured drug concentrations between the FPIA and HPLC methods was calculated based on actual measurements using the following formula: Degree of overestimation (％) ＝[(FPIA value-HPLC value)/HPLC value]×100
Test Items
Clinical laboratory data was used as the data of VCM measurement data of the day.
Clinical laboratory tests for total bilirubin (T bil), glutamyl oxaloacetic transaminase (GOT), glutamyl pyruvic transaminase (GPT), alkaline phosphatase (ALP), g glutamyl transpeptidase (g GTP), lactate dehydrogenase (LDH), blood urea nitrogen (BUN) and serum creatine (Cr) levels were conducted, and the conditions of infection were assessed by bacterial culture, C reactive protein (CRP) levels, white blood cell (WBC) counts and body temperature. In addition, various patient background factors, including age, body weight, present illness, past medical history, nephropathy, hepatopathy, duration of VCM administration, doses and coadministered drugs, were analyzed. The analysis of the pharmacokinetics parameter was done with two point of the value after 2 hours from administration and the trough value, these two values are the study state.
Furthermore, using the concentration of VCM measured by the FPIA method, the initial values of the kinetic parameters of VCM were calculated by the Sawchuk-Zaske method. Then, half-life and distribution volume were calculated using Bayesian analysis software (Higuchi, Kyushu University, Japan).
The clinical eŠect was evaluated with CRP, WBC and body temperature.
The onset of side-eŠects, such as hearing impairment, red neck syndrome, hepatic and renal dysfunctions was studied.
Analysis items
The correlation between the drug concentration as measured by the FPIA and HPLC methods was assessed using regression analysis of all 116 samples. The correlation between overestimation and various clinical laboratory test results was then evaluated using regression analysis.
The relationships between patient background factors and eŠectiveness and side-eŠects of therapy and between overestimation was analyzed for each patient. The clinical condition of the patient was assessed as``Signiˆcantly improved'' when the levels of WBC count, CRP level and body temperature decreased and the elimination of MRSA was conrmed;``Improved'' when the three laboratory data showed improvement levels, even though the elimination of MRSA was not conˆrmed; or``Unchanged'' when the three laboratory data did not show any improvement and MRSA was still detected. Hepatic and renal functions at the beginning of and following VCM administration were evaluated according to the side-eŠects grading system proposed by the Ministry of Health , Labour and Welfare of Japan. 7) More than one grade might indicate the possibility of onset of a side-eŠect.
RESULTS
The DiŠerences between FPIA and HPLC Methods a. VCM Concentrations in Standard Serum Solutions
To ascertain the degree of overestimation, standard VCM was dissolved in standard human serum to produce 1, 5, 20, 40 and 60 mg/ml solutions. Although the serum concentrations of VCM determined by the FPIA method were higher than those determined by the HPLC method at all concentrations, the degree of overestimation was less than 30 ％. The tendency was that the lower the VCM concen- Patient No. 1, 12, 15 and 17 were on HD therapy. E‹cacy: ＋ Remarkably improved, ± Improved, -Unchanged Liver dysfunction: Classiˆed by the grade proposed by the Ministry of Health, Labour and Welfare of Japan. Renal dysfunction: -Cr＜2.0 g/dl, ＋ 2.0 g/dl≦Cr＜4.0 g/dl, [ Cr≧4.0 g/dl All data (mean±SD) was calculated by being together all measurement data regardless of trough value or peak value.
Fig. 2. Correlation of the Traugh Overestimation and Clinical E‹cacy and Correlation of the Cmax Overestimation and Clinical E‹cacy
-Unchanged, ± Improved, ＋ Remarkably improved.
tration, the higher the degree of overestimation.
b. Measurements of Patient Serum Samples
Except for 2 of the 116 samples, the concentrations of VCM measured by the FPIA method were higher than those measured by the HPLC method. The degree of overestimation ranged from -21.4％ to 306.3％.
Correlation between the Degree of Overestimation and Laboratory Test Results and the Pathology
The relationship between the degree of overestimation and each set of clinical laboratory test results was assessed by regression analysis. No signiˆcant correlations were observed between the degree of overestimation and the hepatic and renal functions, or other clinical laboratory test results ( Table 2) .
Four patients were on HD, and 49 samples were collected from these patients. The degree of overestimation was 42.4％(40.5％ in the samples obtained from the patients on HD and 72.7％(61.7％ in the remaining samples (68 samples from 14 patients who were not on HD); thus, the degree of overestimation was signiˆcantly smaller in the samples obtained from the patients on HD ( p＜0.01: p＝0.007) (Fig. 1) . Table 3 and Fig. 2 shows the degree of overestimation, kinetic parameters and the eŠectiveness and sideeŠects of therapy for each patient. However, there were no correlations between overestimation and kinetic parameters, or eŠectiveness and side-eŠects of therapy.
To reduce its nephrotoxicity, the trough concentration of VCM is generally set below 10 mg/ml. Therefore, the degree of overestimation was compared between samples containing VCM at concentrations above and below this level. The results showed a signiˆcant diŠerence between the samples of VCM concentration less and those more than 10 mg/ml (80.5％ (82.1％ and 49.0％(31.0％, respectively) (p＝ 0.0038) (Fig. 3) . The tendency was that the lower the VCM concentration, the greater the overestimation. There have been no reports that the overestimation is estimated with over than 10 mg/ml or less than 10 mg/ ml of FPIA method measurement value. It is reported that instability of calibrator is increased at low concentration. The same results were obtained by this 8) comes to the conclusion that the cause of overestimation is to be produced CDP 1, but it did not come to the conclusion that the instability of calibrator is due to CDP 1 because the measurement of CDP 1 was not done in this study.
DISCUSSION
Patients with renal dysfunction produce CDP 1 by retaining VCM in their body for long time; as a result, it has been reported 1,2) that overestimation occurs. There was no correlation between overestimation and half-life.
Hence, the fact that the degree of overestimation was smaller for the patients on HD suggests that TDM can be performed more accurately for patients on HD.
A study on the stability of FPIA calibrators by Morishige et al. 8) reported that, after 30 days of storage at 4°C and 25°C, VCM potency became lower by 20％ and 60％, respectively. It has also been reported that the production of CDP 1 made these FPIA calibrators unstable, thus making overestimation more likely. Moreover, in this study, when concentration of VCM 10 mg/ml or less were compared with concentrations over 10 mg/ml, overestimation occurred more frequently with concentrations of 10 mg/ml or less ( p＝0.0038). The present study revealed that the greater the overestimations, the lower the concentrations of VCM, thus suggesting that the most signiˆcant factor in overestimation was the instability of FPIA calibrators. Therefore, the stability of calibrators is required in order to prevent overestimation. It can be assumed, that if TDM is performed using the FPIA method, the trough level may be raised due to overestimation, which reduces the risk of inducing nephropathy, but on the other hand, lowers the therapeutic value. However, the results of the present study did not show any correlation between kinetic parameters and overestimation and between eŠectiveness and side eŠects of therapy. Hence, we believe that overestimation is not a clinically signiˆcant issue.
Furthermore, overestimation of VCM bears no relation to treatment in terms of eŠectiveness and side eŠects. Moreover, it is unthinkable that the TDM that was used as overestimation data creates problems clinically. Therefore, the TDM of VCM can be carried out by the FPIA method without any problems, even in patients with nephropathy or HD.
